Drugs / Skyrizi
Skyrizi cost
risankizumab-rzaa · AbbVie. Every official price for Skyrizi, side by side, with who pays it.
Short answer
We found no list price published by AbbVie. Medicare Part B pays up to $14.011 per mg for Skyrizi given by IV infusion or injection in a clinic (October 1, 2026 to December 31, 2026). Pharmacies paid an average of $22,795.09–$23,052.15 per pen or syringe (NADAC, Oct 21, 2026). At the FDA label dose of 150 mg at week 0, week 4, then every 12 weeks (an example), one dose (1 × 150 mg pen) comes to $22,795.09 at the average pharmacy acquisition cost. In 2024, Medicare Part D spent $2.5 billion on Skyrizi, an average of $20,459.66 per prescription fill before rebates (CMS). In Medicare Part D, the yearly out-of-pocket limit is $2,100 in 2026 and $2,400 in 2027.136945
Source: FDA, CMS, data.medicaid.gov (NADAC) and Medicare.gov · checked Nov 15, 2026
Skyrizi: the official numbers, by situation
| Price | Amount | Whose price, and who it applies to | Date |
|---|---|---|---|
| List price | Not published | We found no list price published by AbbVie. | — |
| Pharmacy cost (NADAC) one dose: 1 × 150 mg pen (FDA label dose, an example) | $22,795.093 | What pharmacies pay on average (CMS survey). Not a patient price. | Oct 21, 2026 |
| Medicare Part B payment limit per mg, Skyrizi given by IV infusion or injection in a clinic | $14.0111 | What Medicare pays when the drug is paid under Part B (for example, given in a clinic). CMS lists Part B coinsurance for this code as 20%. | October 1, 2026 – December 31, 2026 |
On Medicare drug coverage: 5,386 of 5,492 Part D plans list Skyrizi for 2027 (98%), and 98% of those require prior authorization, in CMS's formulary file published Oct 15, 2026.18 By year and tier
None of these is your price at the counter: that depends on how you pay. Details and sources for each number are further down.
FDA approval
- Skyrizi (risankizumab-rzaa) was first approved by the FDA on Apr 23, 2019, under application BLA761105.8
Every official price
| Price | Amount | What it is | Date |
|---|---|---|---|
| Maker's list price (WAC) | Not published | We found no current list price on AbbVie's own pages, so we do not show one. | — |
| Medicare Part B payment limit Skyrizi given by IV infusion or injection in a clinic (risankizumab-rzaa) · HCPCS J2327 | $14.0111 | Per 1 mg, when given in a clinic or hospital outpatient setting and paid under Part B. CMS lists Part B coinsurance for this code as 20%. | October 1, 2026 – December 31, 2026 |
| Pharmacy acquisition cost (NADAC) Skyrizi 150 mg/mL pen | $22,795.093 | Per pen or syringe ($22,795.09 per mL × 1 mL). The national average price pharmacies pay to buy it. | Oct 21, 2026 |
| Pharmacy acquisition cost (NADAC) Skyrizi 150 mg/mL syringe | $22,924.373 | Per pen or syringe ($22,924.37 per mL × 1 mL). The national average price pharmacies pay to buy it. | Oct 21, 2026 |
| Pharmacy acquisition cost (NADAC) Skyrizi 180 mg/1.2 mL on-body | $23,052.153 | Per pen or syringe ($19,210.13 per mL × 1.2 mL). The national average price pharmacies pay to buy it. | Oct 21, 2026 |
| Pharmacy acquisition cost (NADAC) Skyrizi 360 mg/2.4 mL on-body | $22,962.523 | Per pen or syringe ($9,567.72 per mL × 2.4 mL). The national average price pharmacies pay to buy it. | Oct 21, 2026 |
These are prices the drug company, Medicare and pharmacies use. What you pay depends on your coverage; see below. CMS notes that a code's presence in its payment file does not by itself mean Medicare covers the drug.2
What Skyrizi costs at the FDA label dose (example)
In the FDA label section "Moderate-to-Severe Plaque Psoriasis", the dose is 150 mg at week 0, week 4, then every 12 weeks.67 We use it only to show the math with official prices. It is an example, not a dosing recommendation: your dose is your doctor's decision, and other uses on the label have other doses.
150 mg pen prices: NADAC effective Oct 21, 2026. FDA label version 180 (Oct 23, 2026).
| Period | At pharmacy acquisition cost (NADAC) |
|---|---|
| One dose 1 × 150 mg pen: 1 pen | $22,795.093 |
| First 52 weeks 5 × 150 mg pen: doses at weeks 0, 4, 16, 28, 40 | $113,975.453 |
How we count: NADAC $22,795.09 per 150 mg pen (Skyrizi 150 mg/mL pen) times the count. None of these is what you pay at the counter: NADAC is what pharmacies pay to buy the drug.
What Medicare spent on Skyrizi in 2024
CMS publishes what Part D spent on each drug each year. Its spending is the gross drug cost, which includes what Medicare, the plan and the patient paid,11 and it does not reflect manufacturers' rebates.12 CMS lists Skyrizi in 3 rows; together they come to $2.5 billion over 121,579 prescription fills, $20,459.66 per fill.
Medicare Part D, calendar year 2024 (CMS Medicare Part D Spending by Drug, checked Nov 15, 2026).
| Product (as CMS lists it) | Total spending | Fills | People | Per fill | Per person |
|---|---|---|---|---|---|
| Skyrizi On-Body | $390.6 million9 | 19,225 | 4,897 | $20,316.2614 | $79,759.0415 |
| Skyrizi Pen | $1.8 billion9 | 85,713 | 27,003 | $20,782.0814 | $65,966.5315 |
| Skyrizi*16 | $315.6 million9 | 16,641 | 5,557 | $18,964.6414 | $56,791.5315 |
For doses given in a clinic and paid under Part B, CMS's spending is the full value of the drug, including the Medicare payment and what the patient owed.13
Medicare Part B, calendar year 2024 (CMS Medicare Part B Spending by Drug, checked Nov 15, 2026).
| HCPCS code | Total spending | Claims | People | Per claim | Per person |
|---|---|---|---|---|---|
| J2327 Injection, risankizumab-rzaa, intravenous, 1 mg | $76.7 million10 | 8,485 | 3,490 | $9,041.86 | $21,982.86 |
These are totals and averages across everyone in Medicare who used the drug, not a price for one person. Averages per person depend on how long and how much each person used it.
How many Medicare Part D plans list Skyrizi
Every Medicare drug plan in CMS's formulary file (standalone drug plans and Medicare Advantage plans with drug coverage). A plan counts when its drug list has at least one form or strength. Matched by RxNorm code and checked against the FDA NDC Directory. Plan counts, not people; to see your own plan's rules use Medicare Plan Finder.
| Plan year | Plans that list it | Prior auth. | Step therapy | Quantity limit | Lowest tier (plans) |
|---|---|---|---|---|---|
| 2026 | 5,413 of 5,49617 98% | 5,307 | 0 | 5,127 | tier 1: 157 · tier 2: 2 · tier 4: 50 · tier 5: 5,204 |
| 2027 | 5,386 of 5,49218 98% | 5,283 | 0 | 5,123 | tier 1: 122 · tier 2: 1 · tier 4: 46 · tier 5: 5,217 |
Being on a plan's list is not a price: what you pay depends on the tier and your plan. Each plan can divide its tiers in different ways. What prior authorization, step therapy and tiers mean.
Skyrizi's Medicare Part B payment limit, quarter by quarter
HCPCS J2327 (risankizumab-rzaa, per 1 mg), from each quarter's CMS ASP payment limit file. The limit is what Part B pays from; it applies when Skyrizi is given in a clinic and paid under Part B.
| Quarter | Payment limit per 1 mg |
|---|---|
| January–March 2025 | $15.08119 |
| April–June 2025 | $14.85920 |
| July–September 2025 | $14.84021 |
| October–December 2025 | $14.94122 |
| January–March 2026 | $14.93223 |
| April–June 2026 | $14.59924 |
| July–September 2026 | $14.53125 |
| October–December 2026 | $14.01126 |
With Medicare
- What you pay depends on your Part D plan. The rules that apply to every Part D drug, from the deductible to the $2,400 out-of-pocket limit in 2027, Extra Help and the Medicare Prescription Payment Plan, are on one page: Part D costs · payment plan. Free one-on-one help: a SHIP counselor or 1-800-MEDICARE.
- When given in a clinic and paid under Medicare Part B, Medicare's payment is based on the limit above, and CMS lists the coinsurance as 20%.1 A Medicare Supplement (Medigap) policy or Medicare Advantage plan changes what you pay.
With commercial insurance or no insurance
- What you pay depends on your plan's copay or coinsurance. The maker lists its savings and support options here: AbbVie: Skyrizi. We link to it but do not copy its terms.
Which drug, which dose, and whether to start, stop or switch are medical decisions. Ask your doctor or pharmacist.
Get an email when a price or rule changes
Only when an official GLP-1 self-pay price or a Medicare or Medicaid rule changes, at most once a week, with the official source for every change.
Official sources for this page (26)
- CMS: Medicare Part B Payment Limit File (quarterly ASP pricing) · as of Oct 23, 2026
“The absence or presence of a HCPCS code and the payment allowance limits in this table does not indicate whether Medicare covers a drug.”
CMS: Medicare Part B Payment Limit File (quarterly ASP pricing) · as of Oct 23, 2026- data.medicaid.gov: NADAC (National Average Drug Acquisition Cost) 2026 · as of Oct 23, 2026
“Out-of-pocket limit Yearly $2,100 (in 2026).”
Medicare.gov: Medicare costs · as of Oct 23, 2026“Out-of-Pocket Threshold: $2,100 Out-of-Pocket Threshold: $2,400”
CMS: CY 2027 Medicare Advantage and Part D Rate Announcement (Table V-6) · as of Oct 23, 2026“150 mg administered by subcutaneous injection at Week 0, Week 4, and every 12 weeks thereafter.”
FDA label (DailyMed): Skyrizi, version 180 · as of Nov 15, 2026“Injection: 150 mg/mL in each single-dose prefilled pen.”
FDA label (DailyMed): Skyrizi, version 180 · as of Nov 15, 2026“BLA761105 ORIG-1 approved 20190423”
FDA (Drugs@FDA via openFDA): BLA761105 · as of Nov 15, 2026“Skyrizi On-Body: Tot_Spndng_2024 390580004.22, Tot_Clms_2024 19225, Tot_Benes_2024 4897; Skyrizi Pen: Tot_Spndng_2024 1781294228.5, Tot_Clms_2024 85713, Tot_Benes_2024 27003; Skyrizi*: Tot_Spndng_2024 315590527.52, Tot_Clms_2024 16641, Tot_Benes_2024 5557”
CMS: Medicare Part D Spending by Drug, 2024 (data.cms.gov) · as of Nov 15, 2026“J2327 Injection, risankizumab-rzaa, intravenous, 1 mg: Tot_Spndng_2024 76720174.47, Tot_Clms_2024 8485, Tot_Benes_2024 3490”
CMS: Medicare Part B Spending by Drug, 2024 (data.cms.gov), HCPCS J2327 · as of Nov 15, 2026“Drug spending metrics for Part D drugs are based on the gross drug cost, which represents total spending for the prescription claim, including Medicare, plan, and beneficiary payments.”
CMS: Medicare Part D Spending by Drug (about the data) · as of Nov 15, 2026“The Part D spending metrics do not reflect any manufacturers' rebates or other price concessions as CMS is prohibited from publicly disclosing such information.”
CMS: Medicare Part D Spending by Drug (about the data) · as of Nov 15, 2026“Drug spending metrics for Part B drugs represent the full value of the product, including the Medicare payment and beneficiary liability.”
CMS: Medicare Part B Spending by Drug (about the data) · as of Nov 15, 2026“Part D drug spending divided by the number of prescription fills.”
CMS: Medicare Part D Spending by Drug data dictionary · as of Nov 15, 2026“Total Part D drug spending divided by the number of unique beneficiaries utilizing the drug during the benefit year.”
CMS: Medicare Part D Spending by Drug data dictionary · as of Nov 15, 2026“' * ' indicates that the average spending per dosage unit reflects multiple routes of administration of the drug”
CMS: Medicare Part D Spending by Drug data dictionary · as of Nov 15, 2026- CMS: 2026_20260916.zip (Part D formulary file for 2026 plans, published 2026-09-23) · as of Nov 15, 2026
- CMS: 2027_20261008.zip (Part D formulary file for 2027 plans, published 2026-10-15) · as of Nov 15, 2026
“J2327, Inj risankizumab-rzaa 1 mg, 1 MG, 15.081, 20.000, ”
CMS: Medicare Part B ASP payment limit file, January–March 2025 · as of Nov 15, 2026“J2327, Inj risankizumab-rzaa 1 mg, 1 MG, 14.859, 20.000, ”
CMS: Medicare Part B ASP payment limit file, April–June 2025 · as of Nov 15, 2026“J2327, Inj risankizumab-rzaa 1 mg, 1 MG, 14.840, 20.000, ”
CMS: Medicare Part B ASP payment limit file, July–September 2025 · as of Nov 15, 2026“J2327, Inj risankizumab-rzaa 1 mg, 1 MG, 14.941, 20.000, ”
CMS: Medicare Part B ASP payment limit file, October–December 2025 · as of Nov 15, 2026“J2327, Inj risankizumab-rzaa 1 mg, 1 MG, 14.932, 20.000, ”
CMS: Medicare Part B ASP payment limit file, January–March 2026 · as of Nov 15, 2026“J2327, Inj risankizumab-rzaa 1 mg, 1 MG, 14.599, 20.000, ”
CMS: Medicare Part B ASP payment limit file, April–June 2026 · as of Nov 15, 2026“J2327, Inj risankizumab-rzaa 1 mg, 1 MG, 14.531, 20.000, ”
CMS: Medicare Part B ASP payment limit file, July–September 2026 · as of Nov 15, 2026“J2327, Inj risankizumab-rzaa 1 mg, 1 MG, 14.011, 20.000, ”
CMS: Medicare Part B ASP payment limit file, October–December 2026 · as of Oct 23, 2026